Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies

Table 2 Comparison of clinical features between groups according to 1-year virologic response n (%)

	Patients without VR (n = 32)	Patients with VR (n = 18)	P value
Age (yr)1	47 (22-70)	42.5 (33-74)	0.413
Male	22 (68.8)	15 (83.3)	0.328
HBeAg-positive	31 (96.9)	16 (88.9)	0.291
Cirrhosis	8 (25)	4 (22.2)	1.000
Duration of ETV therapy (mo)1	24 (13-48)	36 (17-58)	0.003
Serum ALT level (IU/L)1	34.5 (12-918)	29 (5-1704)	0.210
Serum total bilirubin level (mg/dL)1	0.84 (0.31-1.99)	0.79 (0.28-4.30)	0.869
Serum albumin level (g/dL)1	4.2 (3.6-5.1)	4.3 (3.6-4.9)	0.691
INR1	1.01 (0.93-1.23)	1.02 (0.87-1.30)	0.848
Serum HBV DNA level (log10 IU/mL)1	6.16 (3.85-7.63)	4.24 (2.81-7.08)	< 0.001
Site of ETV-resistant mutations			0.441
rt184	12 (37.5)	7 (38.9)
rt202	14 (43.8)	8 (44.4)
rt173	0 (0)	1 (5.6)
rt169 + rt184	0 (0)	1 (5.6)
rt184 + rt202	5 (15.6)	1 (5.6)
rt184 + rt250,	1 (3.1)	0 (0)
Presence of IVR-3	7 (21.9)	17 (94.4)	< 0.001
Rescue therapy regimens (ADV/LMV vs ADV/ETV)	19 vs 13 (59.4 vs 40.6)	8 vs 10 (44.4 vs 55.6)	0.382

¹Data are expressed as median (range). ADV: Adefovir; ALT: Alanine aminotransferase; ETV: Entecavir; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; INR: International normalized ratio; IVR-3: Initial virologic response at 3 mo; LMV: Lamivudine; VR: Virologic response.